by Stephanie Reid, MD FRCPC
November 18, 2026
Intrahepatic cholangiocarcinoma is a cancer that starts in the small bile ducts inside the liver. Bile ducts are thin tubes that carry bile, a digestive fluid made by liver cells, toward the intestine. Intrahepatic cholangiocarcinoma is the second most common cancer that starts in the liver, after hepatocellular carcinoma. It accounts for about 10% to 15% of these cancers. Because it grows inside the liver and rarely blocks bile flow early, it often causes no symptoms until it is large.
This article explains what intrahepatic cholangiocarcinoma is and how its small-duct and large-duct types differ. It also walks through what your pathology report says about the tumor’s grade, size, margins, lymph nodes, genetic changes, and stage. Cancers that start in the bile ducts outside the liver are described in our article on extrahepatic cholangiocarcinoma.
Intrahepatic cholangiocarcinoma usually develops after years of injury to the liver or its bile ducts. Ongoing injury allows genetic changes to build up in the cells lining the ducts. Many people have no known risk factors. Conditions linked to a higher risk include:
Early intrahepatic cholangiocarcinoma often causes no symptoms. Many tumors are found incidentally on scans done for another reason. As the tumor grows, people may notice pain in the upper right abdomen, weight loss, tiredness, or a poor appetite. Yellowing of the skin and eyes, called jaundice, is less common than with cancers outside the liver. It usually means the tumor has reached a larger bile duct near the center of the liver.
The diagnosis of intrahepatic cholangiocarcinoma usually starts with a CT scan or MRI that shows a mass in the liver. Imaging can suggest the diagnosis, but a tissue sample is almost always needed to confirm it. Doctors usually collect the sample by passing a needle through the skin into the mass, called a core needle biopsy or fine needle aspiration. Sometimes the diagnosis is made only after the tumor is removed by surgery.
Under the microscope, a pathologist sees an adenocarcinoma. This means the cancer cells form glands or tube-like structures within dense, scar-like tissue called desmoplasia. Pathologists often use immunohistochemistry, such as a stain for cytokeratin 7, to confirm that the tumor is made of bile duct-type cells.
No single test proves that a liver adenocarcinoma started there. Cancers from the pancreas, stomach, colon, and other organs can spread to the liver and look very similar. For this reason, your doctors combine the biopsy with imaging of the rest of the body before making the final diagnosis. Imaging also shows whether the cancer has spread to lymph nodes or other organs.
The World Health Organization (WHO) classification of digestive system tumors, 5th edition (2019), divides intrahepatic cholangiocarcinoma into two types. The College of American Pathologists (CAP) reporting checklist uses the same types, so your report may name one of them. The two types start in different parts of the bile duct tree, have different genetic changes, and behave differently.
A variant of the small duct type called cholangiolocarcinoma is made of small, bland cells forming cord-like structures. It has a better outlook than the usual small duct type. Some tumors contain both hepatocellular carcinoma and cholangiocarcinoma. These are reported as combined hepatocellular-cholangiocarcinoma, which is a separate diagnosis.
The grade of intrahepatic cholangiocarcinoma describes how closely the cancer cells resemble normal bile duct cells. Pathologists judge it mainly by how well the cells form glands. The grade helps predict how the tumor will behave and is one factor your care team considers when planning treatment.
For intrahepatic cholangiocarcinoma, the pathologist measures the largest tumor and counts how many separate tumors are in the liver. Both findings help determine tumor stage, because a single tumor 5 cm or smaller is lower stage than a single tumor larger than 5 cm. When there is more than one tumor, the smaller ones may be called satellite nodules. Multiple tumors place the cancer in a higher stage, whatever their size, and are linked to a higher risk of the cancer coming back.
In intrahepatic cholangiocarcinoma, perineural invasion means cancer cells are growing around or along a nerve. It is more common in the large duct type. Nerves can act as a pathway, letting cancer cells travel beyond the visible edge of the tumor. Perineural invasion is linked to a higher chance of the cancer coming back after surgery.
Lymphovascular invasion means cancer cells are seen inside a blood vessel or lymphatic channel. In intrahepatic cholangiocarcinoma, cancer cells in a blood vessel are called vascular invasion, and this finding changes the stage. A single tumor with vascular invasion is staged as pT2, even if it is small.
A margin is the edge of liver tissue that the surgeon cuts to remove the intrahepatic cholangiocarcinoma. The pathologist checks the cut surface of the liver, called the hepatic parenchymal margin. If the surgeon cuts a bile duct, the pathologist checks its margin as well.
Our article on surgical margins in your pathology report explains how margins are examined in different organs.
Lymph nodes are small immune organs that drain fluid from nearby tissues. Intrahepatic cholangiocarcinoma can spread to the lymph nodes near the liver, the bile ducts, and the pancreas. Surgeons often remove these nodes and examine them under the microscope. The American Joint Committee on Cancer (AJCC) 8th edition recommends examining at least 6 nodes for accurate staging.
The report lists the number of nodes examined and how many contain cancer. Our article on lymph nodes in your pathology report explains how to read these numbers.
Biomarker testing is especially important in intrahepatic cholangiocarcinoma, because it has more treatable genetic changes than most other cancers of the digestive system. Testing is recommended for anyone with advanced disease. It is usually done with next-generation sequencing, which checks many genes at once in a tumor sample. A few results, such as HER2, also use tissue stains.
IDH1 and IDH2 are genes that make enzymes used in normal cell metabolism. A mutation in either gene causes the cell to make a substance that blocks normal cell maturation. In a large study of advanced intrahepatic cholangiocarcinoma, about 14% had an IDH1 change and about 4% had an IDH2 change.
FGFR2 is a gene that makes a growth signal receptor. In about 1 in 10 intrahepatic cholangiocarcinomas, the gene joins with another gene, creating a fusion that keeps the growth signal switched on. These fusions are found almost exclusively in the small-duct type.
HER2 is a protein on the cell surface that sends growth signals. HER2 overexpression is uncommon in intrahepatic cholangiocarcinoma and is seen mostly in the large-duct type. It is tested with immunohistochemistry, scored from 0 to 3+, and sometimes with in situ hybridization.
KRAS is a gene that passes growth signals inside the cell. KRAS mutations are found mainly in the large duct type and are linked to a worse outlook.
Sequencing often reports changes in other genes, such as BAP1, TP53, and ARID1A. No targeted drug is approved for cholangiocarcinoma based on these results. These tests can help confirm the small-duct or large-duct type, and they may make you eligible for a clinical trial.
The Biomarkers and Genetic Testing section explains these tests in more detail, including our article on MMR and MSI in gastrointestinal cancers.
The pathologic stage of intrahepatic cholangiocarcinoma is based on the AJCC 8th edition. It combines the tumor findings (pT) and the lymph node findings (pN). Spread to distant organs (M) is usually found on imaging rather than in the surgical specimen. Our article on TNM staging explains the system.
The prognosis for intrahepatic cholangiocarcinoma depends most on whether the tumor can be completely removed. In a large international study of people who had surgery, about 40% were alive five years later. For people whose cancer cannot be removed, only about 5% to 10% are alive at five years. In the trial that led to the approval of durvalumab with chemotherapy, the median survival for advanced cancer was about 13 months.
Findings in the pathology report that are linked to a higher risk of the cancer coming back include:
A tumor with an IDH1 mutation or an FGFR2 fusion can be treated with a targeted drug if it grows after first treatment. Many people live longer than the average figures suggest, and your care team can explain what your own findings mean.
Once intrahepatic cholangiocarcinoma is confirmed, a team that usually includes a liver surgeon, medical oncologist, radiation oncologist, and interventional radiologist reviews the scans and pathology. The first question is whether the tumor can be safely removed.
For advanced cancer, the first treatment is usually gemcitabine and cisplatin chemotherapy combined with immunotherapy:
If the cancer grows after first treatment, the biomarker results guide whether a targeted drug may be considered. Treating the underlying liver disease, such as hepatitis B or C, remains important throughout. Follow-up usually includes regular scans and blood tests, which may include the tumor marker CA 19-9.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name